TrialBritish journal of cancer2019

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.

David Páez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.